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A B s T r A C T
Vasopressin is a critical regulator of water homeostasis. There 
are two major receptors for vasopressin: V1 and V2 receptors. 
disturbances in water balance are commonly encountered in 
clinical practice and can be divided into disorders of urinary 
dilution and concentration. The major representatives of 
such disorders are diabetes insipidus and the syndrome of 
inappropriate secretion of antidiuretic hormone (siAdH). 
recent studies show that genetic forms of nephrogenic 
diabetes insipidus are due to mutations in the genes coding 
for the vasopressin V2 receptor (V2r) or aquaporin-2 
(AQP2). identification of the genes involved and analysis of 
the cellular fate of the V2r and AQP2 mutants are relevant 
for understanding the functioning of the V2r and AQP2 
protein. These developments also have implications for 
future therapeutic options. 
The development of nonpeptide vasopressin receptor 
antagonists (VrAs) offers prospects for the treatment of 
euvolaemic (siAdH) or hypervolaemic hyponatraemia 
(congestive heart failure or cirrhosis). several nonpeptide 
VrAs are now in various stages of clinical trials. At present, 
only conivaptan is registered by the fdA for intravenous 
treatment of euvolaemic and hypervolaemic hyponatremia. 
A recent long-term study comparing tolvaptan with placebo 
in patients with chronic heart failure showed no reduction 
in risk of death and hospitalisation.
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Conivaptan, diabetes insipidus, SIADH, tolvaptan, 
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i N T r o d U C T i o N
Water is essential for living organisms. Human water 
balance is tightly regulated by the integrated action of 
osmoreceptors and volume receptors, thirst, vasopressin, 
and the excretion of water by the kidney.1 Disturbances 
in water metabolism are frequent in clinical practice and 
include well-known syndromes such as diabetes insipidus 
and the syndrome of inappropriate secretion of antidiuretic 
hormone (SIADH). In recent years the pathophysiology 
of these water metabolism disorders has been largely 
unravelled, which has increased the prospects for new 
treatment modalities. 
In this review we will discuss normal water regulation and 
specifically address recent advances in the understanding 
of the role of mutations in the vasopressin receptor and 
their relevance for future treatment strategies.
C U r r E N T  C o N C E P T s  i N  W A T E r 
r E G U l A T i o N
The maintenance of human water balance depends on 
the regulation of water intake (which is governed by the 
sensation of thirst and the availability of water) and of 
water excretion in the kidney, which is under the control 
of the antidiuretic hormone arginine vasopressin (AVP), 
and dependent on the presence of a hypertonic medulla 
and functioning vasopressin type-2 receptors (V2R) and 
aquaporin-2 (AQP2) water channels. 
In normal physiology, arginine vasopressin (AVP) is 
synthesised in the hypothalamus and is secreted into the 
circulation by the posterior pituitary gland, in response 
to an increase in serum osmolality or a decrease in 
effective circulating volume. In general, the plasma sodium 
concentration is the primary osmotic determinant of AVP 
release. The osmoreceptors (specialised hypothalamic 
cells) are extremely sensitive and respond to alterations 
in the plasma osmolality of as little as 1%.2 The osmotic 
threshold for AVP is about 280 mosmol/kg. This system is 
so efficient that plasma osmolality does not vary by more 
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than 1 to 2%, despite wide fluctuations in water intake.3 
Although relatively stable in a healthy person, the set 
point of the osmoregulatory system may be lowered by 
pregnancy, the menstrual cycle, and relatively large, acute 
reductions in blood pressure or circulating volume. 
The sensitivity of the volume receptors is different to that 
of the osmoreceptors. AVP is only secreted nonosmotically 
in humans if there is a large enough change in the effective 
arterial blood volume (approximately 5-10%), usually leading 
to a reduction in (standing) blood pressure.4 In case of such 
large, significant blood volume changes, signals originating 
from the volume receptors override those originating from 
the osmoreceptors.3 AVP secretion may also be stimulated 
by nausea, acute hypoglycaemia, glucocorticoid deficiency 
and smoking.5 The primary stimulus for water ingestion is 
thirst, which is mediated by an increase in plasma osmolality 
(threshold 295 mosmol/kg) or a decrease in blood pressure 
or extracellular volume. Various hormones such as AVP and 
angiotensin II are involved in the stimulation of thirst.
AVP is rapidly metabolised in the liver and excreted by the 
kidney, with a half-life in the circulation of only 15 to 20 
minutes. There are two major receptors for AVP: the V1 
and the V2 receptors. 
V1a receptors are located in vascular smooth muscle cells, 
cardiomyocytes, platelets, hepatocytes and myometrium.6 
The effect of activation of V1a receptors depends on their 
location. V1a receptor activation mediates vasoconstriction, 
vascular smooth muscle cell proliferation, platelet 
aggregation, glycogenolysis and uterine contraction in 
accordance with the above-mentioned locations. The V1a 
receptor also promotes hypertrophic growth of myocardial 
cells. Antagonism may result in increased cardiac output, 
reduced total peripheral resistance and reduced mean 
arterial blood pressure. V1b receptors are localised in the 
anterior pituitary gland and facilitate the release of ACTH. 
V2 receptors are located in the vascular endothelium and 
in the basolateral membranes of the principal cells in the 
cortical and medullary collecting tubules. Activation of 
the endothelial V2 receptor increases the release of factor 
VIII and von Willebrand factor, an effect which is used to 
attenuate an increased bleeding tendency by administering 
the V2 receptor agonist dDAVP. Binding of AVP to the 
V2 receptor in the kidney activates a G-protein mediated 
signalling pathway, involving activation of adenylate cyclase 
and the formation of cyclic adenosine monophosphate 
(cAMP). The subsequent activation of protein kinase A 
promotes the translocation of AQP2 water channels from 
cytoplasmic vesicles to the apical membrane (figure 1). 
Consequently, this usually watertight membrane becomes 
water permeable, thereby allowing the transcellular 
passage of water along the favourable osmotic gradient, 
and through the aquaporin-3 and aquaporin-4 water 
channels, which are present in the basolateral membrane. 
In response to decreased blood AVP levels, the AQP2 water 
channels are modified by ubiquitination, a process in 
which ubiquitin peptides are attached to AQP2 proteins. 
figure 1. Regulation of renal water homeostasis by vasopressin (original figure from reference 15, reprinted with 
permission of the American Physiological Society)
A nephron with a magnified principal cell is shown. Binding of AVP to the V2 receptor in the kidney activates a G-protein mediated signalling 
pathway, involving activation of adenylate cyclase and the formation of cyclic adenosine monophosphate (cAMP). The subsequent activation 
of protein kinase A promotes the translocation of AQP2 water channels from cytoplasmic vesicles to the apical membrane in the cell. The 
membrane becomes water permeable, thereby allowing transcellular passage of water along the favourable osmotic gradient and through AQP3 
and AQP4 water channels (which are present in the basolateral membrane). for further details, see text.
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Ubiquitin is a small protein designed to mark other 
proteins for intracellular destruction. Destruction, or more 
precisely proteolysis, occurs in a barrel-shaped structure, 
the proteasome. Ubiquitin can also mark transmembrane 
proteins, such as receptors, for removal from membranes. 
Thus, AQP2 water channels are removed from the luminal 
membrane by endocytosis and returned to cytoplasmic 
vesicles.7 Apart from this direct effect on water transport, 
AVP also increases sodium transport via the epithelial 
sodium channel (ENaC) and urea transport through the 
UT-A1 transporter.8,9
d i s o r d E r s  o f  W A T E r  M E T A B o l i s M
Disturbances in water homeostasis can be divided into 
disorders of urinary concentration and disorders of urinary 
dilution (table 1). The major examples of such disorders are 
SIADH and diabetes insipidus. 
SIADH is characterised by a nonphysiological release of 
AVP. It is a common problem that can be seen in a wide 
variety of clinical situations. SIADH manifests itself as an 
inability to excrete a free water load, with inappropriately 
concentrated urine, resulting in hyponatraemia and 
hypo-osmolality. The hyponatraemia is initially mediated 
by AVP-induced water retention, the ensuing volume 
expansion results in sodium losses. SIADH may result 
from enhanced hypothalamic secretion of AVP, ectopic 
production of AVP (malignancies), or the administration of 
exogenous AVP or oxytocin. Certain forms of drug-induced 
SIADH may be due to an increased susceptibility to AVP.10 
Recently a genetic form of SIADH was described, which 
could be attributed to a gain-of-function mutation of the 
vasopressin 2 receptor due to a point mutation in the V2R 
gene.11 The result of this mutation is an AVP-independent 
continuous activation of the V2 receptor, which increases 
urinary concentration. This condition has been referred 
to as nephrogenic syndrome of inappropriate antidiuresis 
(NSIAD). Osmotically inappropriate antidiuresis may also 
be caused by stimuli such as hypovolaemia, hypotension 
(cirrhosis, congestive heart failure) or glucocorticoid 
deficiency. In patients with congestive heart failure (CHF) 
or cirrhosis, water retention is an initially beneficial 
defence against decreased cardiac output in CHF or the 
dilated splanchnic circulation in cirrhosis. Current and 
future treatment modalities in SIADH are presented 
in table 1. The very recent development and use of AVP 
type 2 receptor antagonists will extend our therapeutic 
armamentarium (see below).
Diabetes insipidus (DI) is characterised by the production 
of abnormally large volumes of urine that result from either 
a decreased secretion of AVP (central DI) or a diminished 
responsiveness to AVP (renal or nephrogenic DI). Patients 
complain of thirst and polyuria, but clinical signs of 
dehydration are uncommon unless fluid intake is impaired 
or prohibited. Central DI can be caused by a variety of 
congenital, acquired or genetic disorders, though in nearly 
50% of cases it is idiopathic (table 1). Nephrogenic DI (NDI) 
is a congenital or acquired disorder in which hypothalamic 
function and AVP release are normal, but the ability to 
concentrate urine is reduced because of diminished or 
absent renal responsiveness to AVP. Acquired NDI is most 
often caused by electrolyte disturbances (hypocalcemia or 
hypokalaemia ), urinary tract obstruction or exposure to 
certain drugs (e.g. lithium). 
The genetic forms of NDI are related to mutations in the 
AVP V2 receptor or AQP2 gene.12-15 The gene for the AVP 
V2 receptor is located on the X-chromosome, thus NDI 
caused by mutations in the V2 receptor gene are inherited 
and transmitted in an X-linked mode. The AQP2 gene is 
located on chromosome 12,16 and NDI caused by mutations 
in the AQP2 gene is inherited in an autosomal mode. 
Both autosomal dominant and recessive forms have been 
described. Recent studies have provided more insight into 
the impact that various mutations have on the functioning 
of the V2 receptor and the AQP2 protein. Insight into 
these mechanisms provides clues for future therapeutic 
interventions, as is evident from the studies concerning the 
V2 receptor that will be addressed in the next section.
N E P H r o G E N i C  d i A B E T E s  i N s i P i d U s 
A N d  M U T A T i o N s  i N  T H E  V 2 
r E C E P T o r
Likely due to its location on the X-chromosome, 90% of 
the patients suffering from congenital NDI have mutations 
in the V2R gene. Currently, more than 180 V2R gene 
mutations have been described,17 and all these mutations 
result in severely disturbed receptor signalling that 
corresponds to an insensitivity of the renal principal cell for 
AVP. The molecular mechanism causing this insensitivity 
differs among mutants and recent data indicate that one 
of these underlying mechanisms might be treatable in the 
future.
The V2R belongs to the large family of G-protein 
coupled receptors (GPCR) and, based on the underlying 
mechanism, GPCR gene mutations in general and V2R 
gene mutations in particular were recently divided into 
five different classes according to their cellular fate 
(figure 2).18,19
Class I comprises mutations that lead to improperly 
processed or unstable RNA, resulting in the absence of 
a fully translated protein. Class II mutations are mainly 
missense mutations resulting in fully translated proteins, 
but due to a point mutation the receptors are misfolded. 
Instead of being transported to the plasma membrane, 
they are retained in the endoplasmic reticulum (ER). This 
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organelle not only synthesises membrane proteins, but 
also assures that these proteins are properly folded and 
assembled. Misfolded proteins, including V2R mutants, are 
subsequently degraded by the proteasome.20 
Class III and IV mutations also result in fully translated 
proteins. These proteins bypass the quality control 
performed in the ER and are transported to the plasma 
membrane. In the plasma membrane class III mutants 
disturb the binding of the stimulatory Gs protein, leading 
to reduced activation of adenylate cyclase and formation 
of cAMP, while class IV mutants are unable to bind AVP. 
Finally, class V mutations allow normal protein synthesis 
and maturation, but here the protein mutations direct the 
mutant receptor to another organelle in the cell. Due to 
mislocation, the V2R mutant is only briefly available for 
AVP binding.
Intracellular retention of V2R missense mutants in the ER 
and their rapid degradation likely represent the main cause 
for NDI. The extent of ER retention may differ among 
mutants and may represent differences in their folding 
state. This was illustrated by Hermosilla et al., who found 
that only three of eight V2R mutants in NDI were strictly 
kept in the ER, whereas the other five were transported 
to the ER-Golgi intermediate compartment, followed by 
retrograde transport to the ER.21
Although several mutants belong to one class only, others 
display characteristics of several classes. Some, for example, 
are partially ER retained (class II), whereas another fraction 
is expressed at the plasma membrane and exerts a reduced 
activity (class III or IV).19 This partial expression of these 
mutants at the plasma membrane may explain the observed 
small antidiuretic response to high doses of desmopressin 
in NDI patients encoding these mutants.23 
P H A r M A C o l o G i C A l  C H A P E r o N E s  T o 
r E s C U E  C l A s s  i i  V 2 r  M U T A N T
While cell biological studies have revealed that most V2R 
mutants in NDI are retained in the ER, other studies 
have proved that many of these ER-retained receptors 
are intrinsically functional (i.e. are able to bind AVP and 
generate a cAMP cascade). This means that ER retention 
is the main reason for these mutant receptors to cause 
NDI and that drugs that can rescue their cell surface 
expression may be of therapeutic value.24-27 As such, the 
discovery that cell-permeable V1R and V2R antagonists are 
able to enter the cell, stabilise the V2R mutant and rescue 
its cell surface expression (figure 2) was widely hailed as 
a breakthrough. Most though not all ER-retained V2R 
figure 2. Cellular fate of V2R mutants in congenital nephrogenic diabetes insipidus (NDI) and their rescue 
(original figure from reference 15, reprinted with permission of the American Physiological Society)  
A) Classes of V2r mutations in Ndi. in the schematic view of the collecting duct cell, the fate of the different mutation classes is indicated by roman 
numerals. Mutations can lead to incomplete proteins (i); endoplasmic reticulum (Er) retention of full-length proteins (ii); impaired Gs coupling 
(iii); impaired AVP binding (iV); and missorting in the cell (V). see text for details. 
B) rescue of class ii V2r mutants by pharmacological chaperones. Class ii V2r mutants are retained in the Er, but on binding of 
cell-permeable antagonists (CPA), the wild-type structure of the V2r mutant is stabilised, which allows them to exit the Er, mature in the Golgi 
complex, and subsequently translocate to the plasma membrane (1). At the membrane, displacement of the CPA by AVP will allow activation of 
the cAMP cascade (2), the missing step needed for translocation of AQP2 to the apical membrane.
Peters, et al. New aspects of disturbances in water metabolism.
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mutants are rescued and re-expressed at the cell surface 
by these ‘pharmacological chaperones’. To be of therapeutic 
use, the rescuing antagonist needs to be displaced by AVP 
after translocation of the V2R mutant to the basolateral 
membrane. Since the competition between AVP and the 
rescuing ligand at the plasma membrane determines 
functional rescue, low-affinity ligands are deemed to 
be more successful than high-affinity antagonists.28 
Indeed, Bernier et al. recently found that administration 
of a low-affinity V1R antagonist resulted in a small but 
significant reduction in urine production and water intake 
in five NDI patients with class II mutations, thereby 
proving in principle that pharmacological chaperones 
can also rescue V2R mutant activity in vivo.29 Of great 
importance is that this treatment with relatively high blood 
concentrations of V1R antagonist came with a minimum 
of side effects. In vitro data show that at clinically relevant 
low concentrations of antagonists, V2R antagonists yield 
a better functional rescue of V2R mutants than V1R 
antagonists.27 It is therefore anticipated that these drugs 
reduce NDI to a greater extent than V1R antagonists. As 
several of the V1R and V2R antagonists have been or are 
close to FDA approval, it will be exciting to discover to 
what extent they are able to relieve NDI caused by class II 
functional V2R mutants.
A V P  r E C E P T o r  A N T A G o N i s T s
Conventional therapies for euvolaemic (SIADH) or 
hypervolaemic hyponatraemia (congestive heart failure 
(CHF), cirrhosis) including water restriction, hypertonic 
saline, democycline and urea are moderately effective 
and their use is limited by noncompliance or side 
effects. None of these therapies directly addresses the 
pathogenetic mechanism involved, i.e. elevated plasma 
AVP. Many patients with CHF develop hyponatraemia and 
hypervolaemia that is poorly responsive to conventional 
loop diuretics. Hyponatraemia in CHF is associated 
with increased morbidity and mortality, underlining 
the importance of adequate correction of this electrolyte 
disorder. The development of nonpeptide vasopressin 
receptor antagonists (VRAs) has opened a new era in the 
treatment of hyponatraemia. Several of these nonpeptide 
VRAs are now in various stages of clinical trials.
Tolvaptan is a selective V2 receptor antagonist. Schrier 
et al. reported the combined data of two randomised 
trials evaluating 225 outpatients with euvolaemic or 
hypervolaemic hyponatraemia, who were given 15 and 
later 30 or 60 mg tolvaptan over a period of 30 days.30 
Tolvaptan increased average serum sodium concentration 
by 4 to 5 mmol/l throughout the entire treatment period. 
About 25% of the patients withdrew from the trial 
due to side effects. Similar results were obtained with 
conivaptan, which is the only combined V1a and V2 
receptor antagonist that has been approved by the FDA for 
treatment of euvolaemic hyponatraemia. A randomised 
placebo-controlled trial in patients with euvolaemic or 
hypervolaemic hyponatraemia (n=74) showed that serum 
sodium normalised or increased >6 mmol/l within five 
days in 48% of patients who received placebo treatment, 
in 71% of patients who received 40 mg conivaptan, and in 
82% of patients who were given 80 mg conivaptan.31 In this 
short-term study, 5% withdrew from the trial because of 
side effects. Both studies noted hypotension, nausea, thirst, 
constipation, and dry mouth as the main side effects. Two 
other selective V2 antagonists, lixivaptan and SR121463, 
are currently being investigated in phase III trials.
From a clinical perspective, VRAs might become 
important new drugs for the treatment of patients with 
congestive heart failure. In patients with heart failure 
AVP is stimulated, thus causing hyponatraemia and 
impairment of diuresis. Two major randomised trials 
studying the effect of tolvaptan in CHF have been carried 
out. A randomised controlled trial studied 254 patients 
with CHF (NYHA II-III) and compared the effect of three 
different oral doses of tolvaptan for a duration of 25 days.32 
Tolvaptan-treated patients showed a decrease in body 
weight and had small, but significant increases in serum 
sodium concentrations. This effect gradually decreased 
over 25 days. Another major trial randomised 319 patients, 
who required hospitalisation for CHF, to receive placebo, 
30, 60 or 90 mg tolvaptan for 60 days.33 The primary 
endpoint was weight loss after 24 hours, which was greater 
in the tolvaptan group. Additional primary endpoints were 
worsening CHF, death or re-hospitalisation. Although 
there were no differences among the treatment groups, in 
post hoc analysis, 60-day mortality was significantly lower 
in the tolvaptan-treated patients with renal dysfunction 
or severe congestion at baseline. Considering these data, 
long-term benefits of VRAs in patients with CHF could be 
expected. The recent outcome of the EVEREST trial has 
therefore been somewhat disappointing.34 The EVEREST 
trial tested the benefit of tolvaptan, given once a day 
(30 mg vs placebo) in two identical short-term studies 
and a longer-term safety and outcome trial. A total of 4133 
patients were randomised. Although the short-term studies 
showed a change in body weight in favour of tolvaptan 
and modest improvement in dyspnoea and oedema, the 
long-term trial (treatment for a minimum of 60 days, 
median follow-up 9.9 months) demonstrated no reduction 
in risk of death or hospitalisation. A total of 537 patients in 
the tolvaptan group (25.9%) and 543 patients in the placebo 
group (26.3%) died (p=0.68). The other primary endpoint 
of hospitalisation or death from cardiovascular causes 
occurred in 871 patients in the tolvaptan group (42.0%) 
and 829 patients in the placebo group (40.2%, p=0.55). No 
significant worsening of renal function was observed; the 
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main side effects of tolvaptan were dry mouth and thirst. 
Although tolvaptan can be safely used in patients with 
CHF, the lack of an effect on primary endpoints and the 
side effects advocate against its long-term use.
Theory and empirical evidence obtained from animal 
experiments indicate that dual vasopressin V1a and V2 
receptor antagonists might provide greater benefits in 
patients with CHF than selective V2 receptor antagonists.35 
V1a receptor antagonists attenuate vascular smooth muscle 
contraction, resulting in vasodilatation and a decrease 
of systemic vascular resistance. As a consequence, the 
cardiac output may increase. Indeed in an acute study 
intravenously administered conivaptan lowered pulmonary 
capillary wedge pressure and right atrial pressure and 
increased urinary output in patients with CHF.36 No animal 
or human experiments studying the haemodynamic effects 
of tolvaptan have been conducted so far, nor have there been 
trials comparing conivaptan with tolvaptan. Currently a large 
multicentre trial with hard endpoints is underway to examine 
the long-term benefits of conivaptan on exercise tolerance in 
patients with CHF.37 It should be noted that conivaptan has 
only been approved for intravenous use by the FDA. Until 
data from additional clinical trials become available, VRAs 
are not recommended in patients with CHF.
C o N C l U s i o N
In the past years our understanding of AVP-mediated 
urinary concentration has substantially improved with 
the elucidation of the crucial molecular mechanisms 
involved. Research on congenital NDI has led to promising 
therapeutic strategies that mediate an antidiuretic response. 
Advantageous effects of vasopressin antagonists have 
resulted in FDA approval of conivaptan for intravenous 
treatment of patients with euvolaemic or hypervolaemic 
hyponatraemia. However, in patients with congestive 
heart failure the expected beneficial effect of long-term 
use of a selective V2 receptor antagonist on risk of death or 
hospitalisation was not observed.
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